NCT01464034 - A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | Biotech Hunter

Enrollment

136

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

July 31, 2020

Study Completion Date

July 31, 2020

Conditions

Multiple Myeloma

Interventions

DRUG

Carfilzomib

IV over 30 minutes on Days 1,2,8,9,15, and 16 every 28 days

DRUG

Pomalidomide

PO daily on Days 1-21, every 28 Days

DRUG

Dexamethasone

40 mg weekly PO or IV on Days 1, 8, 15, and 22, every 28 days.

Trial Locations (9)

Columbia University, New York

University of Pennsylvania Abramson Cancer Center, Philadelphia

Fox Chase Cancer Center, Philadelphia

Duke University Medical Center, Durham

Winship Cancer Institute of Emory University, Atlanta

Indiana University Simon Cancer Center, Indianapolis

MD Anderson Cancer Center, Houston

Fred Hutchinson Cancer Research Center, Seattle

The John Theurer Cancer Center @ Hackensack UMC, Hackensack